Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors
- 31 January 2008
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 108 (1) , 182-190
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Circumventing Resistance to Kinase-Inhibitor TherapyNew England Journal of Medicine, 2006
- Activating Mutations of the Stimulatory G Protein in Juvenile Ovarian Granulosa Cell Tumors: A New Prognostic Factor?The Journal of Clinical Endocrinology & Metabolism, 2006
- Mechanisms Regulating the Constitutive Activation of the Extracellular Signal-Regulated Kinase (ERK) Signaling Pathway in Ovarian Cancer and the Effect of Ribonucleic Acid Interference for ERK1/2 on Cancer Cell ProliferationMolecular Endocrinology, 2004
- Transrepression of Estrogen Receptor β Signaling by Nuclear Factor-κB in Ovarian Granulosa CellsMolecular Endocrinology, 2004
- Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumoursTrends in Endocrinology & Metabolism, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Granulosa Cell Tumor of the OvaryJournal of Clinical Oncology, 2003
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002
- FSH-regulated gene expression profiles in ovarian tumours and normal ovariesMolecular Human Reproduction, 2002
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998